On November 22, 2024, to further facilitate cross-border travel, China decided to include more countries in its visa waiver program and extend the visa-free policy to ordinary passport holders from Bulgaria, Romania, Croatia, Montenegro, North Macedonia, Malta, Estonia, Latvia and Japan on a trial basis from November 30, 2024 to December 31, 2025. 

It is stated that from 30 August 2023, all travelers entering China will no longer need to undergo any COVID-19 testing.

From March 15, China has officially announced the resumption of all kinds of visas, including tourist visas (L Visa), and visa-free policies have been reinstated.

After three years, China announced its reopening from January 8, 2023. Passengers can enter China without quarantine. All you need is a negative PCR result within 48 hours before departure. You do not need to apply for a health code.

Those working in the industry will be aware that the implementation of the IVDR has been far from straightforward, and that there is still a lot of work to be done.

Consumer advocates say the proposed legislation has too many exemptions, while industry groups seek to limit premarket review requirements for legacy tests.

Cytiva cooperates with General Biology (Anhui) Co., Ltd. to build the world's first oligo FlexFactory. The investment scale of the production base reaches hundreds of millions of CNY.

Chinese diagnostic firm Amoy Diagnostics announced on Wednesday that it has entered into a collaboration agreement with French pharmaceutical firm Pierre Fabre to develop companion diagnostic kits in China.

Roche announced on Wednesday that it received CE marking for two of its SARS-CoV-2 tests to run on the firm's new Cobas 5800 system.

On February 21, the Notification on Regulating the Adjustment of Some Medical Service Prices, which included 16 assisted reproductive technologies such as artificial insemination and embryo transfer into Beijing medical insurance, was issued.

The European Union’s In Vitro Diagnostics Regulation (IVDR) is set to take effect May 26, 2022, but a recent effort to amend the transitional provisions of the new regulation may bring some relief.

In case you missed it, the Medical Device Regulations in Canada quietly got updated in December 2020. The new regulation intends to boost post-market safety and requires manufacturers to submit a summary report.

The US Food and Drug Administration on Monday released revised guidance on its regulatory priorities and policies for COVID-19 tests.

The European Union is proposing to delay the go-live date for the incoming medical device regulation pertaining to In Vitro Diagnostics for products that still need assessment of a notified body.

FDA brought medtech up to speed on several key medical device programs during the CDRH Townhall at The MedTech Conference.

Companies that have already registered their devices in the EU will still be able to sell their products in Great Britain until June 2023. From this point, they will be required to register their device for UK Conformity Assessed (UKCA) marking.

The Medical Device Coordination Group (MDCG) has published guidance MDCG 2021-21 “Guidance on performance evaluation of SARS-CoV-2 in vitro diagnostic medical devices” – the document is critical for all manufacturers who manufacture and have CE marked COVID-19 tests under the IVD Directive (IVDD).

Today, WHO and HRP have launched a new guideline to help countries make faster progress, more equitably, on the screening and treatment of this devastating disease.

The landscape of the medical device industry is changing.

On Aug 7th, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology.